MA38797A1 - Protéine de fusion thérapeutique - Google Patents

Protéine de fusion thérapeutique

Info

Publication number
MA38797A1
MA38797A1 MA38797A MA38797A MA38797A1 MA 38797 A1 MA38797 A1 MA 38797A1 MA 38797 A MA38797 A MA 38797A MA 38797 A MA38797 A MA 38797A MA 38797 A1 MA38797 A1 MA 38797A1
Authority
MA
Morocco
Prior art keywords
fusion protein
therapeutic fusion
therapeutic
neprilysin
binds
Prior art date
Application number
MA38797A
Other languages
English (en)
Inventor
Bernd Bohrmann
Per-Ola Freskgard
Hendrik Knoetgen
Jens Niewoehner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48900891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38797(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA38797A1 publication Critical patent/MA38797A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6494—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24011—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral endopeptidase 24.11

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une protéine de fusion comprenant un anticorps dirigé contre aß, une entité de liaison monovalente qui se lie à un récepteur de la barrière hémato-encéphalique et une néprilysine.
MA38797A 2013-08-02 2014-07-30 Protéine de fusion thérapeutique MA38797A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13179056 2013-08-02
PCT/EP2014/066355 WO2015014884A1 (fr) 2013-08-02 2014-07-30 Protéine de fusion thérapeutique

Publications (1)

Publication Number Publication Date
MA38797A1 true MA38797A1 (fr) 2018-06-29

Family

ID=48900891

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38797A MA38797A1 (fr) 2013-08-02 2014-07-30 Protéine de fusion thérapeutique

Country Status (20)

Country Link
US (1) US20160168253A1 (fr)
EP (1) EP3027280A1 (fr)
JP (1) JP2016527260A (fr)
KR (1) KR20160037173A (fr)
CN (1) CN105431203A (fr)
AU (1) AU2014298519A1 (fr)
BR (1) BR112016001782A2 (fr)
CA (1) CA2919325A1 (fr)
CL (1) CL2016000219A1 (fr)
CR (1) CR20160041A (fr)
EA (1) EA201600141A1 (fr)
HK (1) HK1216159A1 (fr)
IL (1) IL243353A0 (fr)
MA (1) MA38797A1 (fr)
MX (1) MX2016001145A (fr)
PE (1) PE20160720A1 (fr)
PH (1) PH12016500123A1 (fr)
SG (1) SG11201600807YA (fr)
WO (1) WO2015014884A1 (fr)
ZA (1) ZA201600086B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252072A3 (fr) 2010-08-03 2018-03-14 AbbVie Inc. Immunoglobuline à double domaine variable et ses utilisations
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
HUE057952T2 (hu) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
EA039366B1 (ru) 2015-06-24 2022-01-19 Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
AU2016283344B2 (en) 2015-06-24 2022-08-04 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing BDNF
WO2016207245A1 (fr) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anticorps anti-tau(ps422) humanisés et leurs méthodes d'utilisation
TWI873952B (zh) 2015-10-02 2025-02-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CA3052936A1 (fr) 2016-12-26 2018-07-05 Jcr Pharmaceuticals Co., Ltd. Proteine de fusion de bdnf et anticorps du recepteur de la transferrine anti-humain
KR102497564B1 (ko) 2016-12-26 2023-02-07 제이씨알 파마 가부시키가이샤 혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
CN110506055A (zh) 2017-02-17 2019-11-26 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
WO2024169990A1 (fr) * 2023-02-13 2024-08-22 浙江大学绍兴研究院 Anticorps bispécifique et son utilisation
WO2025180487A1 (fr) * 2024-02-29 2025-09-04 中国科学院动物研究所 Technologie de dégradation de protéine cible programmée par un polypeptide chimérique

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080274096A1 (en) * 2005-10-03 2008-11-06 Astrazeneca Ab Fusion Proteins Having a Modulated Half-Life in Plasma
US8759297B2 (en) * 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
TW200907056A (en) * 2007-03-28 2009-02-16 Astrazeneca Ab New method
KR101140483B1 (ko) * 2007-05-02 2012-07-11 에프. 호프만-라 로슈 아게 단백질을 안정화시키는 방법
US8946165B2 (en) * 2008-09-29 2015-02-03 The Regents Of The University Of California Compounds for reversing and inhibiting protein aggregation, and methods for making and using them
WO2011160732A1 (fr) * 2010-06-21 2011-12-29 Medimmune, Llc. Variantes de la néprilysine humaine de type protéase
CA2818173C (fr) * 2010-11-30 2022-05-03 Genentech, Inc. Anticorps anti-recepteur de la barriere hemato-encephalique a faible affinite et leurs utilisations

Also Published As

Publication number Publication date
CL2016000219A1 (es) 2016-09-16
WO2015014884A1 (fr) 2015-02-05
KR20160037173A (ko) 2016-04-05
BR112016001782A2 (pt) 2017-08-29
PH12016500123A1 (en) 2016-04-25
EA201600141A1 (ru) 2016-09-30
HK1216159A1 (zh) 2016-10-21
SG11201600807YA (en) 2016-03-30
EP3027280A1 (fr) 2016-06-08
PE20160720A1 (es) 2016-07-28
CN105431203A (zh) 2016-03-23
MX2016001145A (es) 2016-04-29
US20160168253A1 (en) 2016-06-16
ZA201600086B (en) 2017-04-26
AU2014298519A1 (en) 2016-02-04
CR20160041A (es) 2016-02-08
CA2919325A1 (fr) 2015-02-05
IL243353A0 (en) 2016-02-29
JP2016527260A (ja) 2016-09-08

Similar Documents

Publication Publication Date Title
MA38797A1 (fr) Protéine de fusion thérapeutique
EP3877416A4 (fr) Anticorps anti-cd45 et leurs conjugués
MA43576A (fr) Anticorps anti-lag3 et fragments de fixation à l'antigène
MA41669A1 (fr) Anticorps se liant a tau
EP3512549A4 (fr) Anticorps se liant à cd3
EP3411069A4 (fr) Anticorps humanisés anti-cd3, conjugués et leurs utilisations
BR112016007112A2 (pt) Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação
IL287938A (en) Drug antibody conjugates
EP3307274A4 (fr) Anticorps anti-cd123 et conjugués de ceux-ci
EP3710484A4 (fr) Anticorps de liaison à ctla-4 et leurs utilisations
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
EP3299383A4 (fr) MODIFICATION SPÉCIFIQUE DE L'ANTICORPS PAR UN PEPTIDE DE LIAISON À IgG
MA55347A (fr) Anticorps anti-lag3 et fragments de fixation à l'antigène
MA42808A (fr) Anticorps de liaison à l'il-8 et leurs utilisations
CR20140585A (es) Proteinas de union a antigeno st2
MA52626A (fr) Anticorps anti-cd63, conjugués et leurs utilisations
MA41313A (fr) Anticorps de liaison de la protéine april modifiés
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
IL272361A (en) Antibody binding active alpha-synuclein
IL286483A (en) Claudin-6 antibodies and drug conjugates
MA49977A (fr) Combinaisons pharmaceutiques comprenant un anticorps anti-ly75
EP3613770A4 (fr) Anticorps monoclonal à pd-l1
EP3441088A4 (fr) Conjugué anticorps-médicament comprenant un anticorps modifié
EP3416986A4 (fr) Protéine de fusion à un anticorps et compositions associées permettant de cibler un cancer
TR201819828T4 (tr) Anti-fosfolipaz d4 antikoru.